Ricevi le ultime notizie sulle azioni PharmaCyte Biotech con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PMCB

Ultime notizie per

PharmaCyte Biotech

PharmaCyte Biotech Inc

AIM ImmunoTech

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

Genprex

GT Biopharma

HCW Biologics

IN8bio

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Oragenics

Onconetix

Polyrizon

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revolution Medicines

SILO Pharma

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

PharmaCyte Biotech (PMCB) Previsione

Notizie

Utili

Quote.Nav.option-chain

Guidance

Vendite allo scoperto

Rapporto azionario

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Comments

PharmaCyte Biotech Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO